



Scioderm, Inc. to Present Data from Phase 2b Study of Zorblisa™ (SD-101) at the debra International Congress

Durham, N.C. (September 9, 2014) --- Scioderm, Inc., today announced Dr. Robert Ryan, president and chief executive officer, will present at the Dystrophic Epidermolysis Bullosa Research Association (debra®) International Congress, Saturday, September 20, 2014 at 12:40 pm CEST at the Espaces CAP – 15 1/13 Quai de Grenelle in Paris, France. Dr. Ryan will provide an update of the development program for their lead investigational therapy, Zorblisa™ (SD-101), including data from their recently completed Phase 2b study (SD-003). Zorblisa is in late stage clinical development for the treatment of skin blistering and lesions associated with inherited Epidermolysis Bullosa (EB), a pediatric orphan disease.

About Zorblisa (SD-101)

Zorblisa is a proprietary topical therapy being developed for the treatment of patients with EB for which there is no effective treatment. Previous clinical studies indicated that Zorblisa can be useful in the treatment of EB. The SD-003 study was a double-blind, randomized, placebo-controlled, dose-response trial to evaluate the efficacy and safety of different dosage strengths of Zorblisa in the treatment of EB.

About Scioderm, Inc.

Scioderm received Breakthrough Therapy designation for Zorblisa from the FDA, as well as orphan drug designation from the FDA and EMA. In addition, Scioderm was recently selected as a 2013 “Fierce Top 15” company by FierceBiotech, considered as one of the top 15 emerging companies in the biotech industry. Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address diseases with critical unmet medical needs, including orphan products. The company is headquartered in Durham, North Carolina. Additional information about Scioderm can be found at www.sderm.com.

About Epidermolysis Bullosa (EB)

Epidermolysis bullosa (EB) is a rare genetic disease in which the patients have fragile skin susceptible to blistering and tearing. Patients with EB have painful blisters affecting a substantial percentage of their bodies and wounds that can lead to infection and scarring. There is currently no effective treatment for EB. Current standard of care consists of bandaging and bathing the open wounds to prevent infection and trying to manage patients’ pain.

Forward Looking Statement

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Scioderm disclaims any intent or obligation to update these forward-looking statements.

Scioderm Investor Contact:

Robert Coull
Chief Operating Officer
(919)-824-2594
robert.coull@sderm.com

Scioderm Media Contacts:

Andrea Flynn, Ph.D.
Russo Partners LLC
(646) 942-5631
andrea.flynn@russopartnersllc.com

Julia Jackson
Cooney/Waters Group
(212) 886-2249
jjackson@cooneywaters.com